Cargando…

T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers

Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Seraceni, Silva, Zocca, Elena, Cervone, Tamara Emanuela, Tomassetti, Flaminia, Polidori, Isabella, Valisi, Massimiliano, Broccolo, Francesco, Calugi, Graziella, Bernardini, Sergio, Pieri, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396988/
https://www.ncbi.nlm.nih.gov/pubmed/35997354
http://dx.doi.org/10.3390/diseases10030049
_version_ 1784772035942023168
author Seraceni, Silva
Zocca, Elena
Cervone, Tamara Emanuela
Tomassetti, Flaminia
Polidori, Isabella
Valisi, Massimiliano
Broccolo, Francesco
Calugi, Graziella
Bernardini, Sergio
Pieri, Massimo
author_facet Seraceni, Silva
Zocca, Elena
Cervone, Tamara Emanuela
Tomassetti, Flaminia
Polidori, Isabella
Valisi, Massimiliano
Broccolo, Francesco
Calugi, Graziella
Bernardini, Sergio
Pieri, Massimo
author_sort Seraceni, Silva
collection PubMed
description Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selected 23 people in low-antibodies (Group 1, N = 8), high-antibodies (Group 2, N = 9), and negative control groups (Group 3, N = 6). SARS-CoV-2-specific humoral and cellular responses were analyzed at 8 months after two doses of Pfizer BioNTech, evaluating anti-RBD (Receptor Binding Domain) and RBD-ACE2 (Angiotensin Converting Enzyme-2) blocking antibodies in sera through a Chemiluminescence Immunoassay (CLIA) and T-cells through the IGRA test in heparinized plasma. Moreover, lymphocyte subtyping was executed by a flow cytometer. Statistical analysis was performed. Results: The data confirmed that RBD and RBD-ACE2 blocking ACE2 antibody levels of Group 1 were significantly lower than Group 2; p < 0.001. However, T-cells showed no significant difference between Group 1 and Group 2. Conclusions: This work suggests the need for new strategies for booster doses administration.
format Online
Article
Text
id pubmed-9396988
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93969882022-08-24 T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers Seraceni, Silva Zocca, Elena Cervone, Tamara Emanuela Tomassetti, Flaminia Polidori, Isabella Valisi, Massimiliano Broccolo, Francesco Calugi, Graziella Bernardini, Sergio Pieri, Massimo Diseases Brief Report Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selected 23 people in low-antibodies (Group 1, N = 8), high-antibodies (Group 2, N = 9), and negative control groups (Group 3, N = 6). SARS-CoV-2-specific humoral and cellular responses were analyzed at 8 months after two doses of Pfizer BioNTech, evaluating anti-RBD (Receptor Binding Domain) and RBD-ACE2 (Angiotensin Converting Enzyme-2) blocking antibodies in sera through a Chemiluminescence Immunoassay (CLIA) and T-cells through the IGRA test in heparinized plasma. Moreover, lymphocyte subtyping was executed by a flow cytometer. Statistical analysis was performed. Results: The data confirmed that RBD and RBD-ACE2 blocking ACE2 antibody levels of Group 1 were significantly lower than Group 2; p < 0.001. However, T-cells showed no significant difference between Group 1 and Group 2. Conclusions: This work suggests the need for new strategies for booster doses administration. MDPI 2022-07-31 /pmc/articles/PMC9396988/ /pubmed/35997354 http://dx.doi.org/10.3390/diseases10030049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Seraceni, Silva
Zocca, Elena
Cervone, Tamara Emanuela
Tomassetti, Flaminia
Polidori, Isabella
Valisi, Massimiliano
Broccolo, Francesco
Calugi, Graziella
Bernardini, Sergio
Pieri, Massimo
T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title_full T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title_fullStr T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title_full_unstemmed T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title_short T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
title_sort t-cell assay after covid-19 vaccination could be a useful tool? a pilot study on interferon-gamma release assay in healthcare workers
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396988/
https://www.ncbi.nlm.nih.gov/pubmed/35997354
http://dx.doi.org/10.3390/diseases10030049
work_keys_str_mv AT seracenisilva tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT zoccaelena tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT cervonetamaraemanuela tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT tomassettiflaminia tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT polidoriisabella tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT valisimassimiliano tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT broccolofrancesco tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT calugigraziella tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT bernardinisergio tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers
AT pierimassimo tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers